Additional Supporting Information may be found in the online version of this article.

HEP_26225_sm_SuppFigS1.tif2039KSupporting Figure S1: Serum markers of cell death and adiponectin in all patient cohorts. The cell death markers M30 and M65 as well as adiponectin are shown for healthy controls, moderately overweight (“lean”) NAFLD patients and the super-obese NAFLD cohort. All patients exhibited higher cell death compared to healthy controls. Adiponectin was not only significantly reduced in “lean” NAFLD and super-obese NAFLD, but in addition super-obese NAFLD patients had lower adiponectin serum concentrations than “lean” NAFLD.
HEP_26225_sm_SuppFigS2.tif4579KSupporting Figure S2: (A) The bile acid synthesis intermediate cholestenon and serum cholesterol do not differ between the groups. (B) The amount of cholesterol within the liver tissue did not differ between NAFL and NASH patients.
HEP_26225_sm_SuppFigS3.tif3380KSupporting Figure S3: In HepG2 cells, treated with FFA, we found a significant induction of Cyp7A1 (A) and NTCP (B), which could be attenuated by CDCA co-treatment, indicating a dysregulation of baseline SHP activity by FFA abundance, similar to the clinical findings. Expression of SHP (C) itself was significantly reduced by adiponectin, FFA or both. Again addition of CDCA abolished this effect. LXRa (D) as well SREBPc1 (E) were not altered on the level of mRNA expression by FFA, adiponectin, CDCA or combinations thereof. Cell viability, analyzed by MTT test (F) was similar in all experimental conditions. * = p ≤ 0.05; ** = p ≤ 0.001; *** = p ≤ 0.0001 vs. Control cells.
HEP_26225_sm_SuppFigS4.tif70KSupporting Figure S4: Regulatory gene expression. mRNA expression of p21, FASN and SREBP1 was not changed between the “lean” NALFD, NAFL or NASH group.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.